Directors Dealings
Director dealings are proprietary transactions by executives, which are reportable under Art. 19 MAR. The publication of these transactions is an important contribution to the prevention of insider dealing and market manipulation. In addition, knowledge of such transactions is of great importance to the market, as these transactions provide indications of management's assessment of the company's future business prospects. The information presented here relates to companies that are under the supervision of BaFin.
PharmaSGP Holding SE: A reportable insider transaction was published on 8th August 2025. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 8th August 2025,
The Insider Transaction was made by FUTRUE GmbH 
. The transaction toke place on 7th August 2025. . The aggregated volume was 24.444,00 EUR, based on an average price of 28,00 EUR. The nature of the Investment was not specified.
PharmaSGP Holding SE: A reportable insider transaction was published on 7th August 2025. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 7th August 2025,
The Insider Transaction was made by FUTRUE GmbH . The transaction toke place on 6th August 2025. . The aggregated volume was 42.140,00 EUR, based on an average price of 28,00 EUR. The nature of the Investment was not specified.
PharmaSGP Holding SE: A reportable insider transaction was published on 5th August 2025. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 5th August 2025,
The Insider Transaction was made by FUTRUE GmbH . The transaction toke place on 4th August 2025. . The aggregated volume was 14.000,00 EUR, based on an average price of 28,00 EUR. The nature of the Investment was not specified.
PharmaSGP Holding SE: A reportable insider transaction was published on 5th August 2025. The reporting obligation was triggered by a person related to Management Board.
Transaction reporting date: 5th August 2025,
The Insider Transaction was made by Rudolf, Michael . The transaction toke place on 31st July 2025. . The aggregated volume was 116.732,00 EUR, based on an average price of 28,00 EUR. The nature of the Investment was not specified.
PharmaSGP Holding SE: A reportable insider transaction was published on 4th August 2025. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 4th August 2025,
The Insider Transaction was made by Fischer, Dr. Clemens . The transaction toke place on 1st August 2025. . The aggregated volume was 169.736,00 EUR, based on an average price of 28,00 EUR. The nature of the Investment was not specified.
PharmaSGP Holding SE: A reportable insider transaction was published on 28th July 2025. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 28th July 2025,
The Insider Transaction was made by FUTRUE GmbH . The transaction toke place on 25th July 2025. . The aggregated volume was 125.748,00 EUR, based on an average price of 28,00 EUR. The nature of the Investment was not specified.
PharmaSGP Holding SE: A reportable insider transaction was published on 24th July 2025. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 24th July 2025,
The Insider Transaction was made by FUTRUE GmbH . The transaction toke place on 23rd July 2025. . The aggregated volume was 186.760,00 EUR, based on an average price of 28,00 EUR. The nature of the Investment was Buy.
PharmaSGP Holding SE: A reportable insider transaction was published on 23rd July 2025. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 23rd July 2025,
The Insider Transaction was made by FUTRUE GmbH . The transaction toke place on 19th July 2025. . The aggregated volume was 15.120,00 EUR, based on an average price of 28,00 EUR. The nature of the Investment was not specified.
PharmaSGP Holding SE: A reportable insider transaction was published on 19th May 2025. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 19th May 2025,
The Insider Transaction was made by FUTRUE GmbH . The transaction toke place on 15th May 2025. . The aggregated volume was 12.750.000,00 EUR, based on an average price of 25,00 EUR. The nature of the Investment was Buy.
PharmaSGP Holding SE: A reportable insider transaction was published on 25th November 2024. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 25th November 2024,
The Insider Transaction was made by FUTRUE GmbH . The transaction toke place on 21st November 2024. . The aggregated volume was 12.145.250,00 EUR, based on an average price of 24,05 EUR. The nature of the Investment was Buy.
PharmaSGP Holding SE: A reportable insider transaction was published on 25th April 2022. The reporting obligation was triggered by a person related to Closely associated.
Transaction reporting date: 25th April 2022,
The Insider Transaction was made by FUTRUE GmbH . The transaction toke place on 22nd April 2022. . The aggregated volume was 208.180,53 EUR, based on an average price of 23,13 EUR. The nature of the Investment was Buy.
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Equity Story | 66 | 6th August 2025 | EQS Group AG | EQS |
| Corporate Research | 0 | - | - | Corporate Research |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.